ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ARNA Stock Price » ARNA Stock News

Arena Share News

 Arena Pharmaceuticals (mm) Stock Price
ARNA Stock Price
 Arena Pharmaceuticals (mm) Stock Chart
ARNA Stock Chart
 Arena Pharmaceuticals (mm) Stock News
ARNA Stock News
 Arena Pharmaceuticals (mm) Company Information
ARNA Company Information
 Arena Pharmaceuticals (mm) Stock Trades
ARNA Stock Trades

Arena Pharma Finance Chief Hoffman To Leave Company

DOW JONES NEWSWIRES Arena Pharmaceuticals Inc. (ARNA) said its Chief Financial Officer Robert Hoffman has taken a new position in the health-care industry and will leave the company after it reports its full-year 2010 results. Hoffman is a veteran of the biopharmaceutical company, having served as CFO since December of 2005 and having been with the company since 1997. "Robert has built a strong finance team at Arena, and we are focused on ensuring a smooth transition when he departs next month," said President and Chief Executive Jack Lief. Arena said Jennifer Bielasz and Carolyn Felzer will "continue to play key leadership roles in Arena's finance department" in the interim. Arena in January said it planned to cut its U.S. work force by about one-fourth, or 66 employees, as the company continued to focus on regulatory approval of its proposed diet drug lorcaserin. The U.S. Food and Drug Administration had rejected the drug in October because of questions about its effectiveness, as well as the drug's association with breast-tumor growth in female rat studies. Shares of Arena closed at $1.66 and were inactive after hours. The stock has fallen 46% in the past year. -By Nathan Becker, Dow Jones Newswires; 212-416-2855; nathan.becker@dowjones.com;

Stock News for Arena (ARNA)
DateTimeHeadline
03/27/201507:59:45Arena Investors Need To Pay Attention To Competition
03/23/201508:49:56Arena Pharmaceuticals Could Have Better Luck In Quarter 2
03/23/201506:51:27Vivus: Qsymia Sales Slip, Company Needs To Shift Into Gear
03/22/201512:56:03Biotech Stocks: 2 to Avoid, 1 to Buy
03/21/201505:11:59Orexigen - Contrave Scripts Up, Equity Down, Approval In Europe...
03/18/201517:46:50Statement of Changes in Beneficial Ownership (4)
03/16/201509:51:47Vivus' Qsymia Breaks 3-Week Stagnancy, Could Start Upward Trend
03/16/201508:27:08Who Will Be Orexigen's Ex-U.S. Partner? My Bet Is On Takeda
03/15/201520:45:03Orexigen - Contrave Scripts Rise Over 6%, But The Focus Is On...
03/13/201517:44:08Vivus - Qsymia Scripts Pass 11,000 For First Time In 2015
03/11/201508:26:11Arena Scripts Still Slower Than Needed - Are Downgrades In The...
03/10/201502:21:06Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep...
03/10/201502:07:01Arena - Belviq Ads Slow Substantially - Eisai Promises Seem To...
03/09/201510:37:08Orexigen's Contrave Blunder Due To Weak Intellectual Property...
03/04/201517:55:55Statement of Changes in Beneficial Ownership (4)
03/03/201516:26:44Current Report Filing (8-k)
03/02/201520:07:03Arena's (ARNA) CEO Jack Lief on Q4 2014 Results - Earnings Call...
03/02/201516:01:00Arena Pharmaceuticals Provides Corporate Update and Reports Fourth...
03/01/201517:35:17Notable earnings after Mondayâs close
02/23/201511:00:10Orexigen: Contrave Scripts Pass 9,000 - Closing In On Qsymia

Arena Pharmaceuticals and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad